Companies / Novenda Technologies Health Renewable Chemistry
Novenda Technologies Health Renewable Chemistry
Geleen, The Netherlands
Novenda Technologies develops and manufactures 3D printing solutions for specialized applications, including dental products.
Novenda Technologies Health Renewable Chemistry, based in Geleen, The Netherlands, has 2 investors on file, among them Borski Fund and Brightlands Venture Partners. Its site was last checked 6 Nov 2026: site answers.
Investors
2 investors on file| Investor | Evidence | Type |
|---|---|---|
| Portfolio page | Venture capital | |
| Portfolio page | Venture capital |
More from Borski Fund
19 companies on its checked portfolioIts portfolio leans to Healthcare & Biotech (28%), AI & Machine Learning (21%), Industrial & Manufacturing (17%).
More from Brightlands Venture Partners
30 companies on its checked portfolioIts portfolio leans to Healthcare & Biotech (45%), AI & Machine Learning (25%), Consumer (8%).
See Brightlands Venture Partners' full profile · Who invests alongside it
A company is shown only after its own site answers and carries its name. Sites are checked again on a schedule, because domains lapse and get bought. Round stages and dates come from Fundup AI; investor links come from portfolio pages and rounds; other facts name their source when you point at them. How we grade the data
Get Novenda Technologies Health Renewable Chemistry and its investors as data
Look up any company's investors, or any investor's full portfolio, through one API key or MCP. A free account also opens Ask AI searches and alerts when Borski Fund adds a company.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/companies/novenda.com/investors
# also
GET /v1/companies/novenda.com
GET /v1/companies/novenda.com/news